Ohr Pharmaceutical to purchase ophthalmology assets from SKS Ocular

Ohr Pharmaceutical has entered into an agreement to acquire ophthalmology assets from SKS Ocular, the company announced in a news release. Under the agreement, Ohr will acquire a sustained-release technology platform currently in development. The company will also obtain a line of preclinical sustained-release product candidates for the treatment of glaucoma, retinal disease and other eye diseases. The transaction is expected to be finalized by the end of the month.